Skip to main content

EDITORIAL article

Front. Pharmacol., 02 June 2023
Sec. Neuropharmacology
This article is part of the Research Topic Neurovascular Dysfunction After Brain Injury View all 7 articles

Editorial: Neurovascular dysfunction after brain injury

  • 1The 1st Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 2Loma Linda University Medical Center, Loma Linda, CA, United States
  • 3Southwest Hospital, Army Medical University, Chongqing, China

Editorial on the Research Topic
Neurovascular dysfunction after brain injury

Till now, our understanding of neurovascular dysfunction in brain injuries was greatly expanded. Emerging experimental investigations suggested vascular failure is one of the key pathogenic factors, which essentially underlies the damaging secondary events, featured in early capillary permeability disruption leading to cerebral edema, inflammation, and eventual neuron death. At delayed phases, vascular remodeling, particularly in angiogenesis and enhanced endothelial-derived trophic factor secretion, may promote endogenous neurogenesis and neural restoration. Hence, novel strategies targeting early and delayed neurovascular dysfunction, might provide promising opportunities to improve clinical outcomes for patients following brain injuries. The goal of this Research Topic is to concentrate on the recent findings in the pathophysiology, diagnosis, and potential therapeutic targets of neurovascular changes following brain injuries.

In the Research Topic, three excellent reviews presented the advances in the pathophysiology and prognosis of neurovascular events following serial brain injuries. Luo et al. focused on the interaction between various components of the neurovascular unit and SUMOylation, and highlighted the importance of SUMOylation in neurovascular remodeling following acquired brain injury (ABI). Eastin et al. summarized the clinical findings of delayed revascularization in acute ischemic stroke patients. The existing evidence supports improved outcomes after subacute revascularization beyond 4.5 h of stroke onset in selected patients with favorable image characteristics. Chen et al. systematically reviews the pathophysiological changes of myelin sheath injury after Subarachnoid hemorrhage (SAH). They proposed that the precise prevention and treatment of myelin injury should focus on the spatiotemporal characteristics of myelin sheath changes and the initiation, intersection, and common action points of pathophysiological mechanisms, emphasizing the big picture other than details, and actively exploring different treatment methods.

Moreover, the original researches provided the therapeutic targets for potential medical translation. Chen et al. explored metabolomic alterations in mice after cerebral ischemia-reperfusion by employing metabolomic analysis coupling with GC-TOF-MS and UPLC/Q-TOF-MS. Their results showed several simultaneously differentially expressed metabolites and enriched pathways were significantly altered following ischemia-reperfusion. These varied metabolites are important for determining the cellular pathologic status of neuronal cells and their viability, and might be developed as potential molecular markers that can be helpful for therapeutic decision-making. Ma et al. explored the therapeutic effects of 9-phenanthrol after traumatic brain injury (TBI) in rats, and found that it hinders the expression and activity of MMP-9 by impeding TRPM4 channel and represses the destruction of BBB, thereby preventing vasogenic brain edema. Xu et al. performed a case-control study to investigate the correlation between DNA methylation and mRNA expression of the glutathione S-transferase alpha 4 (GSTA4) gene and the risk of intracranial aneurysm (IA) in the Chinese Han population. Their results suggested that GSTA4 methylation and mRNA expression may be reliable predictive markers of the occurrence of female IA.

Hopefully, the studies addressing our Research Topic will help understand the mechanisms underlying neurovascular dysfunction after brain injuries, and may provide promising targets to improve clinical outcomes in patients.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: brain injury, vascular remodeling, vascular injury, neurovascular dysfunction, functional outcome

Citation: Cheng C, Huang L, Guo Z and Chen T (2023) Editorial: Neurovascular dysfunction after brain injury. Front. Pharmacol. 14:1222328. doi: 10.3389/fphar.2023.1222328

Received: 14 May 2023; Accepted: 25 May 2023;
Published: 02 June 2023.

Edited and reviewed by:

Nicholas M. Barnes, University of Birmingham, United Kingdom

Copyright © 2023 Cheng, Huang, Guo and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chongjie Cheng, chengcj@hospital.cqmu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.